FDA Regulatory Toxicology Consulting
A drug can be clinically successful, commercially promising, and still carry an environmental problem nobody planned for.
That usually does not show up in the first investor deck.
It does not get much airtime in early product meetings.
And it definitely does not sound exciting at kickoff.
Until it becomes a filing issue.
A founder says the company has a regulatory roadmap.
The slide looks polished.
The milestones look neat.
The dates seem aggressive, but still believable.
An investor flips through it and thinks one thing:
Can I trust this?
That is the real test.
A startup can lose value long before anything officially goes wrong. No recall.No warning letter.No failed company announcement. Just growing doubt. An investor starts asking harder questions.The next round takes longer.The valuation discussion gets a little less confident.Then a little less generous. Why? Because valuation is not driven by promise alone.It is driven by how […]
The timeline looked brilliant. Prototype by June.Verification by September.FDA meeting by November.Submission next year. Clean. Sharp. Reassuring. Then reality showed up. One design change delayed testing.A risk issue changed the evidence plan.FDA feedback raised questions the team had not built for.Suddenly, the timeline that looked so certain started behaving like fiction. That is the problem […]
Everything looks fine until FDA responds. The roadmap is on track. The milestones are moving. The team is hitting deadlines. Then the feedback arrives. FDA wants clarification on intended use. The evidence does not fully support the claims. A design choice creates new questions about risk. The submission path no longer looks as simple as […]
A medical device company can look perfectly organized on paper and still be heading toward a regulatory mess. The timeline may look polished.Prototype by Q2. Verification by Q3. Submission next year. Investors feel reassured.The team feels productive.The board sees movement. Then one FDA meeting changes everything. The claims are too broad. The evidence plan is […]
The deal closed.
Capital transferred. Board seats assigned. Milestones locked in. Everyone moved on.
Then, six months later, a quiet update arrived in the investor’s inbox:
“FDA has requested additional data.”
Timelines shifted. Burn rate climbed. The next round became a conversation nobody wanted to have. The investment wasn’t struggling because of the product — it was struggling because regulatory risk had been left unattended after the term sheet was signed.
This is more common than most investors realize.
An investor once reviewed two startups in the same week.
Both had regulatory issues.
One deal moved forward.
The other was declined immediately.
An investor once reviewed a data room with over 300 regulatory documents.
Policies. SOPs. Test reports. Slide decks. Validation summaries.
Everything looked thorough.
Then a single question changed the entire deal:
“Where is the evidence that this pathway actually holds?”
